news Aspen Park acquires rights to castration resistant prostate cancer drug 30 September 2015 | By Victoria White APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer...
news UbiVac and Janssen to develop vaccine to intercept oral cancer 30 September 2015 | By Victoria White Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
news LDC and Infinity to work together on oncology drug discovery 29 September 2015 | By Victoria White LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
news MedImmune and 3M partner to develop novel TLR agonist cancer therapies 25 September 2015 | By Victoria White TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
news Study highlights the potential of FAK inhibition in fighting cancer 25 September 2015 | By Victoria White Researchers discovered that FAK inhibition can modulate the balance of immune cells in a tumour enabling an immune response to destroy the cancer cells...
news New collaboration to interpret human proteome information 25 September 2015 | By Victoria White The team of researchers will comprehensively study human proteomes with the aim of turning the vast amount of molecular information into designs for new reagents, equipment, workflows, assays and software...
news Regeneron and ETI team up to discover monoclonal antibodies 24 September 2015 | By Victoria White Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
news MRC Technology & University of Lausanne collaborate on MALT1 inhibitors 24 September 2015 | By Victoria White Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
news MISSION Therapeutics receives funding for DUB cancer programme 24 September 2015 | By Victoria White Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
news H3 and Selvita extend precision cancer drug collaboration 22 September 2015 | By Victoria White The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
news BerGenBio presents positive preclinical data on BGB324 21 September 2015 | By Victoria White The data highlights that BGB324 used in combination with immune checkpoint inhibitors in mouse carcinoma models showed enhanced tumour clearance compared with checkpoint inhibition alone...
article Drug Target Review – Issue #3 2015 21 September 2015 | By Drug Target Review Included in this issue: Drug Development, Microfluidics, Proteomics, Ion Channels, GPCR, Imaging, Flow Cytometry, Enzymes
news Dr Jeanette Wood joins Nuevolution as Scientific Advisor 21 September 2015 | By Victoria White Dr Wood's expertise and experience to support Nuevolution in developing its pipeline in oncology, inflammation and immuno-oncology...
news Selvita expands its operations into the US 21 September 2015 | By Victoria White Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc...
article Microfluidic technology: the next-generation drug discovery tool 21 September 2015 | By Kimberly Plevniak (Kansas State University), Mei He (Kansas State University) Microfluidic miniaturisation, or the so-called ‘lab-on-a-chip’ concept, now encroaches on the fields of biology, medicine and pharmacology, and the nature of microfluidic technology (small volumes and high-throughput integration of fluid connections) means that it is outperforming conventional bench work. There has been an incredible need for microfluidic technology in the…
